Cascade CGM 15-day Performance Assessment

NCT ID: NCT04099043

Last Updated: 2020-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-28

Study Completion Date

2019-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To validate the feasibility of a 15-day wear period of the Cascade CGM system

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess a 15-day wear period for the Cascade CGM. This study includes ten subjects who will interface with the system and take finger stick BGM glucose values for calibration. The wear period includes four in-clinic days frequent blood draws and eleven at home days at a single testing site.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Continuous Glucose Monitoring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Continuous Monitoring

Single Arm, Randomized

Group Type EXPERIMENTAL

Cascade Continuous Glucose Monitoring System

Intervention Type DEVICE

Continuous Glucose Monitoring for 15 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cascade Continuous Glucose Monitoring System

Continuous Glucose Monitoring for 15 days

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Signed informed consent form

* Diagnosis of type 1 or type 2 (on insulin therapy) diabetes mellitus for at least 6 months
* 18 years of age or older
* Currently self-monitoring capillary blood glucose (on average at least three times per day or more) or on a CGM for at least three months
* Willing to have blood glucose levels manipulated into high and low glucose levels during in clinic days if deemed appropriate per the protocol based on insulin use.
* Willing to follow all study procedures, including attending all clinic visits during which a venous line will be inserted for blood sampling, wearing CGM sensors for entire study, performing fingertip glucose tests for self-monitoring and calibration, and keeping a diary of activities.
* Be willing to wear two investigational CGM devices.

Exclusion Criteria

* • Known allergy to medical grade adhesives

* Magnetic Resonance Imaging (MRI) scheduled during CGM sensor wear period
* Persons with type 2 diabetes using diet and exercise only for diabetes management
* Used an investigational drug within 30 days prior to study entry
* Hematocrit \< 32% (obtained during screening)
* Inadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal
* Symptomatic coronary artery disease with a history of angina, or history of a myocardial infarction or coronary intervention (e.g., percutaneous transluminal coronary angioplasty \[PTCA\], stent placement), or coronary artery bypass graft (CABG) within the past six months
* Diagnosis of the following diabetic autonomic neuropathies: orthostatic hypotension, heart rate anomalies, gastroparesis
* Cerebrovascular incident within the past six month
* History or presence of eczema, psoriasis, atopic or contact dermatitis
* Subject is pregnant at the start of the study.
* Current use or within one-week exposure to topical medications at the proposed insertion sites
* Seizure disorder (epilepsy)
* Malignancy within the past five years, except basal cell or squamous cell skin cancers
* Major surgical operation within 30 days prior to screening
* Other medical conditions that would pose safety concerns, interfere with study conduct or seriously compromise study integrity (reason for exclusion will be clearly documented by investigator or designee)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

WaveForm Technologies Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maja Navodnik Peložnik, MD

Role: PRINCIPAL_INVESTIGATOR

Splošna bolnišnica Celje

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Splošna bolnišnica Celje

Celje, , Slovenia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovenia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PR-19-0032

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.